# Molecular and Genetic Diagnosis and Targeted Therapy of Myeloproliferative Neoplasms

Guest Editors:

**Dr. Jinming Song**
Department of Hematopatholology and Lab Medicines, Moffitt Cancer Center, Tampa, FL 33612, USA

**Dr. Ling Zhang**
Department of Hematopatholology and Lab Medicines, Moffitt Cancer Center, Tampa, FL 33612, USA

**Dr. Andrew Kuykendall**
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA

Deadline for manuscript submissions:
**15 November 2024**

## Message from the Guest Editors

Dear Colleagues,

Myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and MPN NOS, are among the most common myeloid neoplasms. Their treatments and their prognosis are different. However, they can show overlapping clinical presentations and are sometimes difficult to distinguish from each other. Therefore, it is critical to perform correct diagnosis and stratification on patients with MPNs. With the advancement of new technologies such as NextGen sequencing, there has been rapid progress in the understanding about the pathogenesis, the diagnosis, the prognosis, and the targeted therapy of MPNs. The purpose of this Special Issue is to present the current advancements in the diagnosis and the prognosis prediction of MPNs. This Special Issue welcomes reviews as well as original research articles. The submission deadline will be extended to May 2024.

mdpi.com/si/164025

**Special** Issue

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us